Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms

MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers.
The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept.
'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.'
The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines.
'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.'
Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines.
About Ethris
Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives.
For more information, visit www.ethris.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Time Business News

3 hours ago

• Time Business News

Prozenith Reviews 2025: The Pink Salt Trick That's Melting Fat Fast!

Official Website: Click Here What is ProZenith? ProZenith is a natural dietary supplement formulated to support effective weight management and overall well-being. It is designed for individuals seeking to enhance their metabolism, increase energy levels, and support fat burning without the use of harsh chemicals or stimulants. By promoting the body's natural ability to burn fat and boost energy, ProZenith helps users achieve and maintain a healthier lifestyle. The supplement is manufactured in FDA-registered and GMP-certified facilities, ensuring its quality and safety. It also supports better mental clarity, digestive health, and immune function. With consistent use and alongside a balanced diet and exercise, ProZenith becomes a reliable ally for anyone on a weight loss or wellness journey. Its plant-based formula makes it a suitable option for those who prefer natural health solutions. Users often report improvements not only in physical performance but also in mood, focus, and daily motivation. The Science Behind ProZenith ProZenith operates on the scientific principle of metabolic enhancement. It helps the body enter a state where fat is used as the primary source of fuel rather than carbohydrates, a process similar to ketosis. This metabolic shift increases energy efficiency and encourages fat loss. Additionally, it supports hormonal balance and appetite regulation, helping reduce unnecessary cravings. This supplement promotes better nutrient absorption and reduces bloating, which further supports the weight loss process. By combining natural compounds known for their holistic benefits, ProZenith addresses various aspects of health to provide a science-backed, safe path to sustainable weight management. Ingredients of ProZenith The ingredients in ProZenith are carefully selected natural compounds known for supporting weight management, energy production, and overall wellness. Each component plays a unique role in promoting metabolism, enhancing fat burning, reducing inflammation, and supporting hormonal balance. Pumpkin Seed Pumpkin seed is renowned for its high antioxidant content and essential fatty acids, which work synergistically to support prostate and urinary health. These nutrients help regulate hormonal balance, reduce inflammation, and protect against oxidative stress. Regular consumption can lead to improved bladder control and decreased discomfort, enhancing daily comfort and urinary function. Lycopene Lycopene is a potent antioxidant primarily found in tomatoes, celebrated for its ability to neutralize harmful free radicals and prevent cellular damage. This compound contributes significantly to immune system support and reduces inflammation throughout the body. Its protective effects extend to promoting heart health and maintaining a healthy prostate, making it a vital nutrient for overall wellness. Broccoli Broccoli is a nutrient-dense vegetable rich in sulforaphane, a natural compound with powerful detoxifying and anti-inflammatory properties. Sulforaphane helps protect cells from damage, supports the body's detoxification pathways, and enhances immune defenses. Additionally, broccoli supports digestive health by improving gut function and reducing inflammation in the digestive tract. Beta Sitosterol Beta Sitosterol is a plant-derived sterol known for its ability to improve urinary flow and support prostate health. It helps maintain balanced cholesterol levels and promotes hormonal equilibrium, which is essential for men experiencing symptoms of an enlarged prostate. Beyond urinary benefits, Beta Sitosterol also supports cardiovascular health and overall well-being. Pygeum Africanum Bark Extracted from the African cherry tree, Pygeum Africanum Bark has a long history in traditional medicine for supporting urinary tract and prostate health. It helps reduce inflammation, ease discomfort during urination, and lessen the frequency of nighttime bathroom visits. Its anti-inflammatory and soothing properties contribute to improved urinary flow and enhanced quality of life. Benefits Accelerated Fat Burning: Helps your body shift into a fat-burning mode by enhancing metabolism, promoting sustainable weight loss. Helps your body shift into a fat-burning mode by enhancing metabolism, promoting sustainable weight loss. Appetite Control: Naturally reduces cravings and supports better portion control to help avoid overeating. Naturally reduces cravings and supports better portion control to help avoid overeating. Increased Energy Levels: Boosts energy without relying on stimulants, helping you stay active and alert throughout the day. Boosts energy without relying on stimulants, helping you stay active and alert throughout the day. Enhanced Mental Clarity: Supports cognitive functions like focus, memory, and motivation—key for staying consistent with health goals. Supports cognitive functions like focus, memory, and motivation—key for staying consistent with health goals. Improved Digestive Health: Aids gut function by reducing bloating and enhancing nutrient absorption for better overall health. Aids gut function by reducing bloating and enhancing nutrient absorption for better overall health. Immune System Support: Strengthens your body's natural defenses to keep you healthier while managing weight. Pros Natural formula Supports weight loss Boosts energy Enhances focus Improves mood Reduces cravings Promotes fat burning Aids digestion Non-GMO and stimulant-free Backed by a money-back guarantee Cons Only available online Not suitable for children Results may vary Requires consistent use How To Use? Take two ProZenith capsules daily with a glass of water, preferably before meals. For best results, follow a consistent routine and support it with a healthy diet and regular physical activity. This helps maximize the supplement's benefits and promotes long-term well-being. Any Side Effects? ProZenith has no side effects when taken as directed, thanks to its natural, non-GMO, plant-based ingredients. Users commonly report increased energy levels and enhanced metabolism without any discomfort or adverse reactions. Its gentle and carefully crafted formula is designed for daily use and is well-tolerated by most individuals. This makes ProZenith a safe and reliable option for those looking to support their health and weight management naturally, without the worry of unwanted side effects or harsh stimulants. Money Back Guarantee ProZenith comes with a 60-day money-back guarantee, giving you the confidence to try it risk-free. If within 60 days you feel the supplement doesn't meet your expectations or you're not satisfied with the results, you can easily request a full refund by contacting customer support. This generous refund policy ensures you have ample time to evaluate the product's effectiveness without any financial worry. With this guarantee, ProZenith offers a worry-free opportunity to invest in your health and well-being, making it a trustworthy choice for those seeking natural support. Pricing & Availability Basic Pack (2 Bottles): $158 + $9.99 Shipping Most Popular (3 Bottles): $207 with Free Shipping Best Value (6 Bottles): $294 with Free Shipping and the biggest savings Where to Buy? ProZenith can be purchased exclusively through its official website. This ensures you're getting the authentic product, complete with quality assurance, secure checkout, and eligibility for bonuses and money-back guarantees. Avoid third-party platforms that may sell counterfeit versions. Buying directly also gives you access to customer support and the latest promotional offers. For your safety and best experience, always purchase from the verified source. Conclusion As an expert, I strongly recommend ProZenith for anyone seeking a natural and effective solution to support weight management and overall wellness. This supplement uses powerful plant-based ingredients that work together to boost metabolism, increase energy, and promote fat burning without harsh chemicals or stimulants. It also enhances mental clarity and supports digestive health, making it ideal for daily use. With regular use, ProZenith helps achieve sustainable results while strengthening the immune system. Supported by positive customer reviews and a 60-day money-back guarantee, it offers a risk-free way to improve your health. If you want a reliable, natural boost to your wellness journey, ProZenith is definitely worth trying. >> (LIMITED SUPPLIES) Click Here to Buy ProstaVive for The Lowest Price Online << TIME BUSINESS NEWS

Business Upturn

10 hours ago

• Business Upturn

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Business Wire

20 hours ago

• Business Wire

Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding BLCO should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.